INDEX

ABBREVIATIONS
constituents of smokeless tobacco, 70
ABRASION (DENTAL)
defined, 128
relation to smokeless tobacco, 130
ABUSE LIABILITY OF NICOTINE
defined, 145, 157
evidence for abuse potential, 166-167
experimental studies, 157-166
implications of studies, 162
pharmacodynamic effects, 158
research needs, 184
self-administration, 159-162
ACANTHOSIS
clinical report, 115-118
defined, 113
ADENOCARCINOMA
relation to snuff use, 48
ADOLESCENT USE
attitudes, 24
data criteria, 17
ethnic groups, 20
males vs. females, 20
National Program Inspection study, 24
peer and family influences, 24
rural vs. urban areas, 20
ADULT USE
patterns, 16-17
ADVISORY COMMITTEE TO THE SURGEON GENERAL, REPORT
carcinogens revealed, vii
cancerous conditions, xxii
oral leukoplaikia, viii
organization of report, xvii
overview, xx-xxii
premalignant oral health conditions, xxi
review methods, xix-xx
ALCOHOL CONSUMPTION
relation to smokeless tobacco, 35
ANIMAL MODELS
bioassays with chewing tobacco, 79, 82-83
bioassays with constituents of smokeless tobacco, 86-88
bioassays with snuff, 83-86
metabolism of NMOR, 74-75
metabolism of NNK, 71-73
metabolism of NNN, 73-74
mutagenicity assays, 88-89
pharmacodynamic effects of nicotine, 158
physiologic effects of nicotine, 178
salivary glands, 126-127
short-term tests, 88-89
ASIAN DATA
case-control studies, 42-43, 119
chewing of quids, 42-43, 50
esophageal neoplasms, 50
rates of oral cancer, 42-43
smokeless tobacco products, 42-43
smoking and oral cancer risk, 43-44
BIOASSAYS FOR CARCINOGENIC ACTIVITY OF CHEWING TOBACCO OR CHEWING TOBACCO EXTRACTS, 80
BIOASSAYS FOR CARCINOGENIC ACTIVITY OF SNUFF OR SNUFF EXTRACTS, 81
BIOASSAYS WITH CHEWING TOBACCO (See also ANIMAL MODELS)
application to the cheek pouch, 79, 82-83
application to the oral mucosa, 79, 82-83
oral administration, 79
skin application, 83
subcutaneous application, 83
BIOASSAYS WITH CONSTITUENTS OF SMOKLESS TOBACCO (See also ANIMAL MODELS)
inducement of tumors, 86-88
BIOSASSAYS WITH SNUFF
(See also ANIMAL MODELS)
application to the lip, oral
mucosa, or cheek pouch, 84-86
oral administration, 83-84
relation to herpes simplex virus,
86-87
subcutaneous administration, 86
Bladder Neoplasms, See URINARY
TRACT NEOPLASMS
Blockade Therapy, See NICOTINE
ADDICTION TREATMENT
BUCCAL CARCINOMA
case studies, 34-36

CALCULUS (DENTAL)
defined, 129
use of smokeless tobacco, 130
CARCINOGENICITY OF TOBACCO-
SPECIFIC NITROSAMINES, 82
CARCINOGENS
daily exposure from snuff and
chewing tobacco usage, 64
in smokeless tobacco, 58-60, 64-65
N-nitrosamines, 58-60, 64
polonium$^{210}$ ($^{210}$Po), 58, 65
polynuclear aromatic hydro-
carbons (PAH), 58, 65
saliva analysis, 64
CARCINOMA IN SITU
defined, 114
diagnoses differ, 123
squamous cell carcinoma study,
120
Cardiovascular System, See
PHYSIOLOGIC EFFECTS OF
NICOTINE
Central Nervous System, See
PHYSIOLOGIC EFFECTS OF
NICOTINE
CHARACTERISTICS OF SMOKE-
LESS TOBACCO PRODUCTS, 6
CHEEK NEOPLASMS
(See also ORAL CANCER)
animal models, 79, 82, 84
case study, 120
CHEMICAL COMPOSITION
processed tobacco, 58
nicotine, 58
CHEMICAL CONSTITUENTS
OF SMOKELESS TOBACCO
carcinogens, 58-59, 60, 64-65
chemical composition, 58

CHEVRON KERATINIZATION
case report, 116-117
defined, 114
CHEWING TOBACCO (See also
SMOKELESS TOBACCO,
BIOASSAYS)
case-control studies, 36, 40
characteristics, 5
plug, 5, 7
twist, 5, 7
Commonalities Between Tobacco
and Other Addictive Substances,
See NICOTINE ADDICTION
CONCEPTUAL MODEL
of smokeless tobacco lesions, 121
CONCEPTUAL NATURE HISTORY
OF ORAL MUCOSAL CHANGES
ASSOCIATED WITH THE USE OF
SMOKELESS TOBACCO, 122
CORONARY AND PERIPHERAL
VASCULAR DISEASE
acute coronary events, 177-178
and nicotine, 177-178
atherosclerosis, 177
effect on platelets, 177
endothelial injury, 177
research needed, 185
ventricular fibrillation, 178

Cotinine, See PHARMACO-
KINETICS OF NICOTINE
CURRENT POPULATION
SURVEY (CPS)
survey data, 12, 14

DATA: ABUSE LIABILITY STUDIES
AT ADDICTION RESEARCH
CENTER, 160
DENTAL CARIES
defined, 128
relation to smokeless tobacco,
129-130
DOSE RESPONSE EFFECTS
(See also ANIMAL MODELS)
and oral leukoplakia, 131
nicotine, 147, 152-153, 158,
182-183

DRUG DEPENDENCE
commonalities between tobacco
and other substances, 146-147,
152-157
defined, 145
physiologic or physical
dependence, 145-146
DYSPLASIA
defined, 114
diagnoses differ, 121, 123
relation to oral lesions, 115-116

Endocrine System, See
PHYSIOLOGIC EFFECTS
OF NICOTINE

EPIDEMIOLOGIC STUDIES
AND SMOKELESS TOBACCO
data from Asia, 42-44
data from North America and
Europe, 33-42
oral cancer, 33-44
other cancers, 47-55

EROSION (DENTAL)
defined, 128

ERYTHROPLAKIA
defined, 113

ESOPHAGEAL NEOPLASMS
case-control study, 39, 48-50
cohort study, 49-50

ESTIMATED EXPOSURE OF U.S.
RESIDENTS TO NITROSAMINES,
64

ESTIMATED RELATIVE RISKS
ASSOCIATED WITH SNUFF USE
FOR CANCERS OF THE ORAL
CAVITY, PHARYNX, AND
LARYNX, CASE-CONTROL
DATA FROM VOGLER ET AL.,
FEMALES ONLY, 38

ESTIMATED RELATIVE RISK FOR
CANCER OF THE HEAD AND
NECK FROM SMOKELESS
TOBACCO USE BY ANATOMIC
SITE, THIRD NATIONAL CAN-
CER SURVEY, MALES ONLY, 39

ESTIMATED RELATIVE RISK OF
ORO-PHARYNGEAL CANCER
ACCORDING TO DURATION OF
SNUFF USE AND ANATOMIC
SITE, WINN ET AL., 41

ESTIMATES OF RELATIVE RISKS
OF BLADDER CANCER IN
PERSONS WHO HAVE EVER
USED CHEWING TOBACCO
AND SNUFF, 53

ETHNIC USE OF SMOKELESS
TOBACCO
of youth, 21-22

Experimental Studies Exposing
Laboratory Animals,
See ANIMAL MODELS

FORMATION OF TOBACCO-
SPECIFIC NITROSAMINES, 60

FREQUENCY OF SMOKELESS
TOBACCO USE IN PAST YEAR,
14

Gastric Neoplasms,
See STOMACH NEOPLASMS

GENERAL PRINCIPLES IN
EVALUATING CARCINOGENIC
RISK OF CHEMICALS OR COM-
PLEX MIXTURES (INTERNATIONAL AGENCY FOR
RESEARCH ON CANCER, xxi

GINGIVAL AND PERIODONTAL
HEALTH
bone loss, 125
effects of smokeless tobacco, 101,
103-104, 123
inflammation, 126
studies in Sweden, 126
studies in the United States, 125

GINGIVAL CARCINOMA
case studies, 34, 36, 44, 120

GINGIVAL RECESSION
Advisory Committee report, viii
defined, 123
related to oral leukoplakia/
mucosal pathology, 112
studies in the United States, 125

GINGIVITIS
defined, 123
relation to smokeless tobacco,
125, 129
studies in the United States, 125

GLYCERINIC ACID
metabolic consequences, 179

HEAD AND NECK NEOPLASMS
case-control study, 38-39, 38-39

HEROIN ADDICTION
THERAPY
model used, 156

HERPES SIMPLEX VOKS
relation to oral cancer, 86-87, 93

HISTORICAL PERSPECTIVE
chewing tobacco, xvii
consequences of use, xviii-xix
decline of use, 5
early uses, xviii-xix, 5
snuff, xvii-xix

HYPERKERATOSIS
cohort study, 117-118
defined, 113
relation to snuff use, 125
HYPERORTHOKERATOSIS
cohort study, 118
defined, 113

HYPERPARAKERATOSIS
cohort study, 118-119
defined, 113

HYPOKALEMIA
nonnicotine metabolic consequences, 179

INHALED SNUFF
relation to nasal carcinoma, 93

Kidney Neoplasms. See URINARY TRACT NEOPLASMS

LARYNGEAL NEOPLASMS
(See also THIRD NATIONAL CANCER STUDY)
case-control study, 37, 38, 50-51

Leukoplakia, Oral. See ORAL LEUKOPLAKIA

LIP NEOPLASMS (See also ORAL CANCER)
animal models, 84-85
case-control study, 36
labial mucosa, 116-117

Looseleaf. See CHEWING TOBACCO

MANUFACTURING TRENDS:
QUANTITIES OF SMOKELESS TOBACCO MANUFACTURED IN THE UNITED STATES FROM 1961 TO 1985 EXPRESSED IN MILLION POUNDS. 8

MEAN FREQUENCY OF SMOKELESS TOBACCO USE DURING LAST 7 DAYS BY ETHNICITY BY MALE RESPONDENTS. 23

METABOLIC PATHWAYS OF NMOR, 74
METABOLIC PATHWAYS OF NNK, 71
METABOLIC PATHWAYS OF NNN, 73

METABOLISM OF CONSTITUENTS OF SMOKELESS TOBACCO
conversion of products, xx-xxi
of NMOR, 74-75
of NNK, 71-73
of NNN, 73-74

MOUTH NEOPLASMS
(See also ORAL CANCER)
case-control study, 36-37, 39, 120

MUCOSAL PATHOLOGY
snuff-induced lesions, 114-116
studies in Scandinavia, 111-112
studies in the United States, 107, 108-109, 110-112

MUTAGENICITY ASSAYS AND OTHER SHORT-TERM TESTS
(See also ANIMAL MODELS)
chewing tobacco, 88
snuff, 88
tobacco-specific N-nitrosamines, 88-89

NASAL NEOPLASMS
posterior nasal space tumors, 48
relation to snuff use. 48

Nass. See ASIAN DATA

NATIONAL BLADDER CANCER STUDY
relation to smokeless tobacco use, 52-53

NATIONAL BLOOD CANCER STUDY
survey data, 16

NATIONAL HEALTH INTERVIEW SURVEY (NHIS)
survey data, 10, 14-15

NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)
survey data, 13-15

NATIONAL PREVALENCE OF CURRENT USE OF SNUFF BY GENDER, AGE, AND RACE FOR 1980 THROUGH 1985. 11

NATIONAL PREVALENCE OF SMOKELESS TOBACCO USE BY ADULT STATUS AND SEX, NIDA SAMPLE, 1985. 13

NATIONAL PREVALENCE OF SMOKELESS TOBACCO USE: DATA SOURCES, 9

NATIONAL SURVEY DATA
conclusions, 24-25
Current Population Survey, 12, 14
discussion of data, 14-15
National Health Interview Survey, 10, 14-15
National Institute on Drug Abuse Household Survey, 13-15
Office on Smoking and Health Surveys, 7, 10, 12, 14
Simmons Market Research Bureau, 10, 12, 14-15
NEUROADAPTATION (See also PHYSICAL DEPENDENCE POTENTIAL OF NICOTINE, PHYSIOLOGIC EFFECTS OF NICOTINE) defined, 143 demonstrated, 153 nicotine, 162

NICOTINE (See also PHARMACOKINETICS OF NICOTINE, NICOTINE ADDICTION, NICOTINE EXPOSURE, ABUSE LIABILITY, PHARMACODYNAMICS OF NICOTINE, PATHOLOGIC EFFECTS OF NICOTINE, AND SMOKELESS TOBACCO) absorption, 141-142, 185 cotinine levels, 143 dependence, 154 distribution, 142 elimination, 142-143 habilitating agent, 58 levels, 143 physical dependence, 162-166 self-administration, 159-161 therapeutic effects, 154-155 turnover, 143

NICOTINE ADDICTION (See also NICOTINE EXPOSURE, PHYSICAL DEPENDENCE POTENTIAL OF NICOTINE) commonalities with other addictive substances, 146-147, 152-157, 184 dose manipulations, 153 encourages other drug use, 184 pattern of use, 152 relation to smokeless tobacco, 58, 144 147, 162, 185 self-administration, 152-153 social tolerance, 156 therapeutic effects, 154-155 tolerance of use developed, 153 treatment for, 155-156

NICOTINE ADDICTION TREATMENT blockade therapy, 156 nicotine gum, 156 pretreatment, 156 substitution, 156 supportive therapy, 156

NICOTINE CHEWING GUM as substitution, 156 reinforcing properties, 166-107 research needs, 184 self-administration, 167

NICOTINE EXPOSURE (See also NICOTINE, NICOTINE ADDICTION) delivery to the central nervous system, 147 other physiological effects, viii, xx, xxvi pharmacokinetics, xxiv, 141-144 peer pressure, 147, 152 reinforcer for animals, 147 relation to addiction, xxiv-xxvi, 144-157

NICOTINE SELF-ADMINISTRATION PATTERNS, 161

NMOR (See also ABBREVIATIONS) metabolism in rats, 74-75

N-NITROSOAMINES (See also CARCINOGENS) exposure in non-tobacco products, 64, 64 in snuff, 60 in tobacco leaves, 59 metabolized by tissue, 70-75 nonvolatile, 60, 62 tobacco-specific, 60, 69 volatile, 60, 61

N-NITROSOAMINES IN SMOKELESS TOBACCO, 59 NNK (See also ABBREVIATIONS) metabolism in rats, 71-73

NNN (See also ABBREVIATIONS) metabolism in rats, 73-74 relation to buccal mucosa, 73 relation to lingual mucosa, 73

NONCANCEROUS CONDITIONS (See also PRECANCEROUS CONDITIONS) relation to smokeless tobacco, 100-105

NONVOLATILE NITROSOAMINES IN SMOKELESS TOBACCO (PPB), 62

OFFICE ON SMOKING AND HEALTH (OSH) survey data, 7, 10, 12, 14

ORAL CANCER (See also ORAL LEUKOPLAKIA, ORAL SOFT TISSUES, LIP NEOPLASMS, MOUTH NEOPLASMS, CHEEK NEOPLASMS, AND TONGUE NEOPLASMS) case studies, 34-41
ORAL CANCER—Cont.
edemiologic studies, 33-55
in rats, 72, 79, 84-86, 89-89

ORAL LEUKOPLAKIA
causation, vii
defined, 113
prospective study, 118
relation to smokeless tobacco, viii, xxiii-xxiv, 107
studies in Scandinavia, 111-112
studies in the United States, 107, 108-109, 110-112

ORAL SOFT TISSUES
clinical reports of lesions, 114-117
cohort studies, 117-119
definitions, 113-114
oral lesions, 119-120
transformation, 113-123

PANCREATIC NEOPLASMS
chewing tobacco use, 54-55
PARANASAL SINUS NEOPLASMS
relation to snuff use, 48

PATHOLOGIC EFFECTS OF NICOTINE AND SMOKELESS TOBACCO
coronary and peripheral vascular disease, 177-178
hypertension, 178
nornicotine metabolic consequences, 179
peptic ulcer disease, 178
pregnancy risks, 178-179

PERIODONTAL TISSUE DEGENERATION (See also MUCOSAL PATHOLOGY, GINGIVAL AND PERIODONTAL HEALTH)
and teenagers, 110

PERMISSIBLE LIMITS FOR INDIVIDUAL N-NITROSAMINES IN CONSUMER PRODUCTS, 65

PHARMACODYNAMICS OF NICOTINE
Liking Scale, 158
Morphine Benzedrine Group Scale, 158
research needs, 158
self-administration
implications, 162

PHARMACOKINETICS OF NICOTINE
absorption, 141-142
cotinine blood levels, 143

PHARMACOKINETICS OF NICOTINE—Cont.
distribution, 142
elimination, 142-143
levels in smokeless tobacco, 141
nicotine blood levels, 143
time course of turnover, 143

PHARYNGEAL NEOPLASMS
case-control study, 37, 38, 39-40
cohort study, 41-42

PHYSICAL DEPENDENCE POTENTIAL OF NICOTINE (See also NEUROADAPTATION)
defined, 145, 162
determination, 153-154
evidence for physical dependence, 157-166
evidence of withdrawal symptoms, 164-166
implications of physical dependence, 166
reinforcement with nicotine gum, 167
studies conducted, 157, 162-163
tobacco withdrawal, 163-164

PHYSIOLOGIC EFFECTS OF NICOTINE (See also NEUROADAPTATION, PHYSICAL DEPENDENCE POTENTIAL OF NICOTINE)
cardiovascular system, 175-176
central nervous system, 147, 176, 183
differentiation possible, 162
differentiation of the endocrine system, 176
pleasant effects produced, 162, 176

PLAQUE
defined, 128
use of smokeless tobacco, 130
Plug, See CHEWING TOBACCO
Polonium210 (210Po), See CARCINOGENS
Polynuclear Aromatic Hydrocarbons (PAH), See CARCINOGENS
POSTERIOR NASAL SPACE TUMORS
relation to liquid snuff, 48

PRECANCEROUS CONDITIONS (See also NONCANCEROUS CONDITIONS)
Advisory Committee Report, xxi
defined, 113
relation to leukoplakia, 119
relation to smokeless tobacco, xxi
SALIVA ANALYSIS
of snuff dippers, 64

SALIVARY GLANDS
effects of smokeless tobacco, 101-105, 126-128

SCHEME LINKING NICOTINE TO FORMATION OF THE PROMUTAGENIC DNA ADDUCT OF-METHYLGLUANINE, 72

SELECTED STUDY SUMMARIES FOR THE NONCANCEROUS ORAL HEALTH EFFECTS FROM THE USE OF SMOKELESS TOBACCO, 100-105

SIALADENITIS
defined, 123
relation to smokeless tobacco, 127
relation to snuff dippers, 127

SIMMONS MARKET RESEARCH BUREAU
survey data, 10, 12, 14-15

SMOKELESS TOBACCO (See also CHEWING TOBACCO, SNUFF)
carcinogenesis associated with, 33-93
chemical constituents, 58-69
cohort studies, 41-42
commonalities with other addictive substances, 146-147, 152-157
conclusions, 24-25, 92-93, 130-131, 182-183
effect on oral leukoplakia/mucosal pathology, 107-112
epidemiologic studies and case reports of oral cancer, 33-44
epidemiologic studies of other cancers, 47-55
evidence for abuse and dependence, 166-167
experimental studies exposing laboratory animals, 78-79
experimental studies of abuse and dependence, 157-166
metabolism of constituents, 70-75
nicotine addiction, 144-146
nicotine exposure, xxiv, 141-185
noncancerous and precancerous oral health effects, xxiii-xxiv, 99-130
pharmacokinetics of nicotine, 141-144
physiologic and pathologic effects, 175-179
prevalence and trends of use, 4-24

193
SMOKELESS TOBACCO—Cont.
product characteristics, 5
research needs, 25, 93-94,
131-132, 184-185
transformation of oral soft
tissue, 113-120
trends in production and sales,
5, 7
trends in self-reported use, 7, 10,
12, 17, 20, 24
SMOKELESS TOBACCO AND HEAD
AND NECK CANCER BY ANA-
TORIC SITE, CASE-CONTROL
DATA FROM VINCENT AND
MARCHETTA, MALES ONLY, 38
SMOKELESS TOBACCO AND
MOUTH CANCER, CASE-
CONTROL DATA FROM
MOORE ET AL., 36
SMOKELESS TOBACCO AND
MOUTH CANCER, CASE-
CONTROL DATA FROM
PEACOCK ET AL., 37
SNUFF (See also SMOKELESS
TOBACCO, BIOASSAYS,
ANIMAL MODELS)
case-control studies, 37, 40
characteristics, 5
dry, 7
historical uses, xviii-xix
levels of carcinogen, 60, 64-66
moist, 7
relation to cancer, 41, 53-55
saliva analysis, 64
SNUFF-DIPPER’S CARCINOMA
defined, 113
exposure to nitrosamines, 64
oral lesions, 120
reports, 35
Scandinavian study, 111
SQUAMOUS CELL CARCINOMA
case studies, 34-36
clinical study, 117
defined, 114
oral lesions, 119-120
snuff and ear neoplasms, 47
STAINING (DENTAL)
defined, 129
STATE AND LOCAL SURVEY
DATA
adolescent use, 17, 20, 24-25
adult use, 16-17
STOMACH NEOPLASMS
relation to smokeless tobacco,
51-52
Substitution Therapy, See
NICOTINE ADDICTION
TREATMENT
SUMMARY OF DATA: LIABILITY
OF NICOTINE AS TOBACCO
SMOKE OR INTRAVENOUS
INJECTIONS, 159
SUMMARY OF REPORTS IN
WHICH NICOTINE WAS AVAIL-
ABLE UNDER INTRAVENOUS
DRUG SELF-ADMINISTRATION
PROCEDURES, 148-151
SUMMARY OF SELECTED CASE
REPORTS, 106
Supportive Therapy, See
NICOTINE ADDICTION
TREATMENT
Surgeon General’s Advisory
Committee on the Health
Consequences of Using Smokeless
Tobacco, See ADVISORY
COMMITTEE TO THE SUR-
GEON GENERAL, REPORT
TEETH
dental caries, 129-130
effect of smokeless tobacco,
128-130
other hard tissue effects, 130
THERAPEUTIC EFFECTS OF
NICOTINE
as an anoretic, 154
mood regulator, 154
performance of cognitive tasks,
154
self-medication, 155
work enhancement, 154
THIRD NATIONAL CANCER
STUDY (TNCS)
bladder cancer, 54
laryngeal neoplasms, 50-51
other cancer sites, 55
stomach neoplasms, 52
TOBACCO SNIFFING
rare practice, xvii
TOBACCO-SPECIFIC
N-NITROSAMINES IN SMOKE-
LESS TOBACCO (PBB), 63
TOBACCO-SPECIFIC
N-NITROSAMINES IN SNUFF,
U.S. BRANDS, 1985, 66
TOBACCO WITHDRAWAL
(See also PHYSICAL DEPEN-
DENCE OF NICOTINE)
evidence of symptoms, 164-166
TOBACCO WITHDRAWAL—
Cont.
study findings, 165
symptoms, 163-164
University of Minnesota
studies, 164-166
TONGUE NEOPLASMS (See also
ORAL CANCER, MOUTH
NEOPLASMS)
case-control study, 36, 120
TRENDS IN PRODUCTION
AND SALES
categories of products, 7
temporal trends, 7
United States Department of
Agriculture (USDA) reports, 5
TRENDS IN SELF-REPORTED
USE: SURVEY DATA
national survey data, 7, 10, 12-15
state and local survey data,
15-17, 20, 24
Twist, See CHEWING TOBACCO
URINARY TRACT NEOPLASMS
case-control studies, 52-54
relationship to smokeless
tobacco, 52-54
USE OF SMOKELESS TOBACCO IN
THE UNITED STATES BY
INDIVIDUALS OVER 21 YEARS
OF AGE, 10
VARIATIONS IN TERMS USED AND
DEFINITIONS PROVIDED FOR
GINGIVITIS AND GINGIVAL RE-
CESSION BY STUDIES CITED, 124
VARIATIONS IN TERMS USED AND
DEFINITIONS PROVIDED FOR
LEUKOPLAKIA/MUCOSAL
PATHOLOGY ASSOCIATED
WITH SMOKELESS TOBACCO
USED BY STUDIES CITED,
108-109
VERRUCOUS CARCINOMA
declared, 114
dysplastic lesions, 131
VOLATILE NITROSAMINES IN
SMOKELESS TOBACCO (PPB),
61
WORLD HEALTH
ORGANIZATION (WHO)
Committee on Drug Dependence,
145
defines oral leukoplakia, 107
differing diagnoses, 123
DISCRIMINATION PROHIBITED. Under provisions of applicable public laws enacted by Congress since 1964, no person in the United States shall, on the grounds of race, color, national origin, handicap, or age, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity, or on the basis of sex, with respect to any education program or activity receiving Federal financial assistance. In addition, Executive Order 11246 prohibits discrimination on the basis of age by contractors and subcontractors in the performance of Federal contracts. And Executive Order 12054 states that the head of each executive branch agency shall ensure that any contractor may discriminate against any employee or applicant for employment because of race, color, religion, sex, national origin, handicap, employment because of age, or because of sexual orientation. Service must be provided in compliance with these laws and Executive Orders.